New AI-based Method Detects Brain Response to MS Treatment
By MedImaging International staff writers Posted on 06 Jul 2019 |
Researchers at University College London {(UCL), London, UK} and King's College London {(KCL) London, UK} have developed a new artificial intelligence (AI)-based method for detecting the brain's response to treatment in multiple sclerosis (MS). The new method has substantially higher sensitivity than conventional, radiologist-derived measures permit.
The researchers studied patients with relapsing–remitting MS who were treated with the disease-modifying drug natalizumab, where serial magnetic resonance imaging (MRI) scans were available before and after initiation of treatment. The team used machine vision to extract an "imaging fingerprint" of the state of the brain from each scan, capturing detailed changes in white and grey matter and yielding a rich set of regional trajectories over time.
In comparison to the conventional analysis of the traditional measures of total lesion and grey matter volume that a radiologist is able to extract, the AI-assisted modeling of the complex imaging fingerprints was able to discriminate between pre- and post-treatment trajectories of change with much higher accuracy. The study demonstrated that AI can be used to detect brain imaging changes in treated MS with greater sensitivity than measures simple enough to be quantified by radiologists, enabling "superhuman" performance in the task. The approach could be used to guide therapy in individual patients, detect treatment success or failure faster, and to conduct trials of new drugs more effectively and with smaller patient cohorts.
Dr. Parashkev Nachev from UCL Queen Square Institute of Neurology who led the study, said, "Rather than attempting to copy what radiologists do perfectly well already, complex computational modeling in neurology is best deployed on tasks human experts cannot do at all: to synthesize a rich multiplicity of clinical and imaging features into a coherent, quantified description of the individual patient as a whole. This allows us to combine the flexibility and finesse of a clinician with the rigor and objectivity of a machine."
Related Links:
University College London
King's College London
The researchers studied patients with relapsing–remitting MS who were treated with the disease-modifying drug natalizumab, where serial magnetic resonance imaging (MRI) scans were available before and after initiation of treatment. The team used machine vision to extract an "imaging fingerprint" of the state of the brain from each scan, capturing detailed changes in white and grey matter and yielding a rich set of regional trajectories over time.
In comparison to the conventional analysis of the traditional measures of total lesion and grey matter volume that a radiologist is able to extract, the AI-assisted modeling of the complex imaging fingerprints was able to discriminate between pre- and post-treatment trajectories of change with much higher accuracy. The study demonstrated that AI can be used to detect brain imaging changes in treated MS with greater sensitivity than measures simple enough to be quantified by radiologists, enabling "superhuman" performance in the task. The approach could be used to guide therapy in individual patients, detect treatment success or failure faster, and to conduct trials of new drugs more effectively and with smaller patient cohorts.
Dr. Parashkev Nachev from UCL Queen Square Institute of Neurology who led the study, said, "Rather than attempting to copy what radiologists do perfectly well already, complex computational modeling in neurology is best deployed on tasks human experts cannot do at all: to synthesize a rich multiplicity of clinical and imaging features into a coherent, quantified description of the individual patient as a whole. This allows us to combine the flexibility and finesse of a clinician with the rigor and objectivity of a machine."
Related Links:
University College London
King's College London
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases